Scientists at Sanofi created digital counterparts of people with Pompe disease to support drug development and advance Pompe disease treatment. In a simulated clinical trial of digital twins with infantile-onset Pompe disease (IOPD), Sanofi’s Nexviazyme (avalglucosidase alfa), an enzyme replacement therapy, outperformed its first-generation Lumizyme (alglucosidase alfa)…
AI
Recent Posts
- Nighttime breathing issues can emerge even with early Pompe care
- When a medical trip feels like a vacation to a child with rare disease
- Newborn screening finds more presumed LOPD cases than expected
- How I’m building a full life while living with Pompe disease
- Chronic pain affects more than 80% of late-onset Pompe disease patients